MG
GMAB icon

Michael Gelband’s Genmab GMAB Stock Holding History

Michael Gelband’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
+43,172
New +$1.15M 0.01% 1018
2024
Q2 		– Sell
-13,015
Closed -$389K – 1686
2024
Q1 		$389K Buy
+13,015
New +$382K ﹤0.01% 1196
2022
Q2 		– Sell
-6,925
Closed -$251K – 2122
2022
Q1 		$251K Buy
+6,925
New +$238K ﹤0.01% 1825

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's GMAB Position: Q2 2026 in Review

Michael Gelband opened a new position in Genmab (GMAB) in Q2 2026: 43,172 shares worth $1.19M. The stake represents 0.01% of the portfolio and ranks #1018 among its holdings. This is a return to the name: Michael Gelband previously reported a position in GMAB as recently as Q1 2024.

Michael Gelband first reported a position in GMAB in Q1 2022 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Michael Gelband held 43,172 shares of Genmab worth $1.19M as of Q2 2026.
  • Genmab was a new Michael Gelband position in Q2 2026.
  • Genmab made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1018 holding.
  • Michael Gelband first reported a position in Genmab in Q1 2022 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.